Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2013 by University Hospital, Rouen
Information provided by (Responsible Party):
University Hospital, Rouen Identifier:
First received: September 13, 2005
Last updated: January 8, 2013
Last verified: January 2013

The objective of the study is to identify and validate predictive markers of anakinra responsiveness in RA patients by a transcriptomic approach.

Patients with active RA (ACR criteria) were given subcutaneous anakinra (100mg/d) 3 associated with metotrexate. Anakinra efficacy was evaluated at week 12, using the EULAR response criteria.

A blood sample was collected just before the onset of anakinra treatment and total RNAs were extracted from the peripheral blood mononuclear cells. The [33P] radiolabeled mRNAs were hybridized (duplicate or triplicate) over a set of 10.000 human cDNA probes spotted at a high density on nylon membranes. Data were normalized and filtered to allow the comparison between RNA samples. Statistical analyses were performed with the R software and hierarchical clustering was performed with the Cluster and Tree View softwares.

Condition Intervention Phase
Rheumatoid Arthritis
Drug: Response to anakinra associated with methotrexate
Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis

Resource links provided by NLM:

Further study details as provided by University Hospital, Rouen:

Study Start Date: June 2003
Estimated Study Completion Date: December 2006

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Is age 18 years old or older Satisfies the 1987 American College of Rheumatology revised criteria for Rheumatoid arthritis Has active disease at the time of randomization as indicated by a DAS28> 5.1 Has a disease at least refractory to DMARDs whose methotrexate or leflunomide Is capable of understanding and signing an informed consent form Agrees to use a medically accepted form of contraception during the study

Exclusion Criteria:

  • Is pregnant or breast-feeding or without contraception Has significant concurrent medical diseases including cancer or a history of cancer within 5 years of entering the study, uncompensated congestive heart failure, significant active infection or any underlying diseases that could predispose subjects to infections (whose tuberculosis) Has renal disease (creatinin clearance level < 30 ml/min) Has allergy to anakinra Has leukopenia (white blood cells < 1.5 x 109 /l
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00213538

Contact: xavier Le louet, MD 0232888265

CHU de rouen - Hôpitaux de Rouen Recruiting
Rouen, France, 76031
Contact: Xavier Le Loët, MD    33 2 32 88 90 19   
Sub-Investigator: Jean-Philippe Salier, PhD         
Sub-Investigator: Maryvonne Daveau, MDPhD         
Sub-Investigator: Thierry Lequerré, MD         
Sub-Investigator: François TRON, MDPhD         
Sub-Investigator: Olivier Vittecoq, MDPhD         
Sub-Investigator: Alain DARAGON, MD         
Sub-Investigator: Othmane Mejjad, MD         
Sponsors and Collaborators
University Hospital, Rouen
Principal Investigator: Xavier Le Loët Rouen University Hospital
  More Information

No publications provided by University Hospital, Rouen

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University Hospital, Rouen Identifier: NCT00213538     History of Changes
Other Study ID Numbers: 2003/020/HP
Study First Received: September 13, 2005
Last Updated: January 8, 2013
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Abortifacient Agents
Abortifacient Agents, Nonsteroidal
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 20, 2014